Compare WEST & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | ASMB |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | 1393 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.8M | 442.9M |
| IPO Year | N/A | 2010 |
| Metric | WEST | ASMB |
|---|---|---|
| Price | $7.90 | $28.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.00 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 971.0K | 153.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.27 | N/A |
| Revenue Next Year | $10.66 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.59 | $13.80 |
| 52 Week High | $8.98 | $39.71 |
| Indicator | WEST | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 60.99 | 49.44 |
| Support Level | $3.82 | $26.50 |
| Resistance Level | $8.98 | $31.11 |
| Average True Range (ATR) | 0.60 | 1.79 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 64.85 | 39.25 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.